Talazoparib/talazopanib will be included in medical insurance in 2025

Talazoparib is a highly effective poly(ADP-ribose) polymerase (PARP) inhibitor that has attracted widespread attention in the field of precision tumor treatment in recent years. It is mainly targeted at patients with defects in the DNA repair pathway of tumor cells. By blocking PARP-mediated single-stranded DNA repair, it aggravates DNA damage and ultimately induces tumor cell apoptosis.

In terms of indications, the drug has been approved for use in two major groups of people: one is adult patients with harmful or suspected harmful germlineBRCA mutation (gBRCAm) and HER2-negative locally advanced or metastatic breast cancer ; The second is combined with enzalutamide (enzalutamide) for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. The common feature of these groups is that tumor cells are defective in DNA double-strand repair, allowing PARP inhibitors to significantly enhance the killing effect.

In overseas clinical practice, the efficacy of talazoparib has been supported by multiple Phase III trials and has been approved for marketing in the United States, the European Union, Japan and other places. The introduction of original drugs in China is accelerating. At present, the drug has been introduced into the country by Pfizer and has been officially launched for the treatment of the above two types of indications. Due to its short launch time, its price and medical insurance negotiations in China are still progressing. Judging from the adjustment trend of the national medical insurance catalog over the years, targeted therapy drugs, especially new drugs with clear molecular targets and outstanding clinical value, are being included in medical insurance at an accelerated pace. Once included in medical insurance, it will significantly reduce patients’ financial burden of medication and improve clinical accessibility.

Overall, the clinical application of talazoparib is in a stage of rapid expansion, and subsequent reductions in medical insurance coverage and price will be key nodes for its market popularity.

Reference materials:https://www.talzenna.com/